| Q26796453 | Advances and challenges in the management of complement-mediated thrombotic microangiopathies |
| Q33421861 | An international consensus approach to the management of atypical hemolytic uremic syndrome in children |
| Q33434103 | Anti-complement-factor H-associated glomerulopathies |
| Q33705135 | Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions: case reports and a review of the evidence for treatment with eculizumab |
| Q43213346 | Case report of atypical hemolytic uremic syndrome with retinal arterial and venous occlusion treated with eculizumab |
| Q91942246 | Comorbidity of inflammatory bowel disease with atypical hemolytic uremic syndrome in pediatric patients |
| Q33417644 | Effect of plasma exchange and immunosuppressive medications on antibody titers and outcome in anti-complement factor H antibody-associated hemolytic uremic syndrome |
| Q42650328 | Factor H autoantibody is associated with atypical hemolytic uremic syndrome in children in the United Kingdom and Ireland |
| Q89373702 | Haemolytic uraemic syndrome |
| Q64975120 | Hemolytic uremic syndrome: differential diagnosis with the onset of inflammatory bowel diseases. |
| Q33419853 | Podocyte dysfunction in atypical haemolytic uraemic syndrome |
| Q40324683 | Successful discontinuation of eculizumab under immunosuppressive therapy in DEAP-HUS. |
| Q90087118 | Successful use of eculizumab to treat atypical hemolytic uremic syndrome in patients with inflammatory bowel disease |
| Q33441880 | Two cases of atypical hemolytic uremic syndrome (aHUS) and eosinophilic granulomatosis with polyangiitis (EGPA): a possible relationship. |